Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 5/20 | 0.41 |
| ▸ | CCND1 | P24385 | 5/20 | 0.41 |
| ▸ | CCND2 | P30279 | 5/20 | 0.41 |
| ▸ | CCND3 | P30281 | 5/20 | 0.41 |
| ▸ | WEE1 | P30291 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069792 | 0.86 | PTK2 (0.44) | KDRPTK2 | |
| SCHEMBL16070248 | 0.85 | FGFR1 (0.38) | PTK2SRC | |
| SCHEMBL17469985 | 0.84 | PTK2 (0.45) | KDRPTK2 | |
| SCHEMBL16070250 | 0.84 | PTK2 (0.45) | KDRPTK2 | |
| SCHEMBL16069790 | 0.84 | PTK2 (0.42) | KDRPTK2 | |
| SCHEMBL16070358 | 0.83 | FGFR3 (0.47) | PTK2 | |
| SCHEMBL16070213 | 0.83 | PTK2 (0.40) | KDRPTK2 | |
| SCHEMBL16069763 | 0.83 | FGFR3 (0.55) | — | |
| SCHEMBL16070209 | 0.82 | FGFR3 (0.41) | KDRPTK2 | |
| SCHEMBL16069930 | 0.82 | PTK2 (0.42) | KDRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | ABL1 59/4885BCR 303/4885MCHR1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.